Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ImmunityBio Inc.

    NASDAQ: IBRX · Real-Time Price · USD
    2.80
    0.04 (1.45%)
    At close: Jun 26, 2025, 3:59 PM
    2.80
    -0.02%
    After-hours: Jun 26, 2025, 06:37 PM EDT
    1.45%
    Bid 2.75
    Market Cap 2.47B
    Revenue (ttm) 31.22M
    Net Income (ttm) -409.1M
    EPS (ttm) -0.57
    PE Ratio (ttm) -4.91
    Forward PE -9.6
    Analyst Buy
    Ask 2.81
    Volume 3,081,970
    Avg. Volume (20D) 9,446,762
    Open 2.75
    Previous Close 2.76
    Day's Range 2.74 - 2.81
    52-Week Range 1.83 - 7.48
    Beta -0.07

    About IBRX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IBRX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    ImmunityBio Inc. is scheduled to release its earnings on Aug 11, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 weeks ago
    +0.38%
    ImmunityBio shares are trading higher after the co... Unlock content with Pro Subscription
    1 month ago
    +3.57%
    ImmunityBio shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight.
    news image

    2 weeks ago · seekingalpha.com

    ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

    ImmunityBio, Inc.'s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva's indications could reach $900 million by 2028, implying a 73% up...

    news image

    3 weeks ago · businesswire.com

    ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This...

    news image

    3 weeks ago · businesswire.com

    ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access au...

    news image

    1 month ago · businesswire.com

    ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

    CULVER CITY, Calif. & RIYADH, Saudi Arabia--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the signing of a strategic Memorandum of Understanding (...

    news image

    1 month ago · zacks.com

    ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

    ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    1 month ago · zacks.com

    ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

    ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago.

    news image

    1 month ago · businesswire.com

    ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) ...

    news image

    1 month ago · seekingalpha.com

    ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

    ImmunityBio, Inc.'s sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a similar indication. The market reacted negatively, dropping IBRX sha...

    news image

    1 month ago · benzinga.com

    ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

    ImmunityBio, Inc. IBRX on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA p...

    news image

    1 month ago · businesswire.com

    ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food and...

    Add to Watchlist